UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) September 16, 1999
-------------
GISH BIOMEDICAL, INC.
(Exact name of Registrant as specified in its charter)
California 0-10728 95-3046028
-------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisidiction of File Number) Identification No)
incorporation)
2681 Kelvin Avenue, Irvine, California 92614
--------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (949) 756-5485
--------------
Not Applicable
--------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS
- --------------------
On September 16, 1999, the Company announced the resignation of Jack W. Brown,
the Company's Chairman and President. A committee of the Board, comprising John
Hagestad, Richard Dutrisac, and Howard Bovers will perform the duties of the CEO
until a successor is chosen.
ITEM 7. EXHIBITS
- ----------------
EXHIBIT NO. DESCRIPTION
- ----------- -----------
99.1 Press Release Dated September 16, 1999
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
GISH BIOMEDICAL, INC.
Date: September 20, 1999 By: /s/ JAMES R. TALEVICH
-------------------------
James R. Talevich
Chief Financial Officer
<PAGE>
EXHIBIT 99.1
PRESS RELEASE DATED SEPTEMBER 16, 1999
GISH BIOMEDICAL ANNOUNCES MANAGEMENT CHANGES
Irvine, California -- September 16, 1999 -- The Board of Directors of Gish
Biomedical, Inc. (Nasdaq: GISH) today announced that Jack Brown had resigned as
Chairman and President. He will become the Managing Director of Product
Development for Gish and will continue to serve as a member of its Board. A
committee of the Board, comprising John Hagestad, Richard Dutrisac, and Howard
Bovers will perform the duties of the CEO until a successor is chosen.
The Board also elected as directors, John W. Galuchie, Jr., President of T.R.
Winston & Co., Inc. and James J. Cotter, Esq., an attorney with the law firm of
Whitman Breed Abbott & Morgan, LLP. James B. Glavin resigned as a director.
This news release contains forward-looking statements concerning the Company's
business and products. Actual results may differ materially depending on a
number of risk factors, including the impact of competition, downward pricing
pressures in the relevant markets, risks related to product performance and the
risks relating to consumer acceptance of the Company's products. These and other
risks inherent in the Company's business are described in the Company's
Securities and Exchange Commission filings, including its Annual Report on Form
10-K. The Company undertakes no obligation to revise the forward-looking
statements contained herein to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
